Physician profile
Chun Chow
NPI 1639589591
$29,724.87
in general payments reported to CMS, 2019-2025
64 companies · $5,257 in 2025
The $5,257 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,136 · 2022: $6,066 · 2023: $7,212 · 2024: $6,054 · 2025: $5,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Travel and Lodging: $1,031 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,349.58 |
| Travel and Lodging | $1,030.56 |
| Education | $142.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,621.78 | 2021-2025 | Briviact, Fintepla, Zilbrysq |
| Abbvie INC. | $2,859.23 | 2021-2025 | |
| Livanova USA, INC. | $1,675.39 | 2022-2023 | Vns Therapy |
| Sk Life Science, INC. | $1,517.25 | 2021-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $1,516.46 | 2021-2025 | Ingrezza, Ongentys |
| Neurelis, INC. | $1,139.66 | 2021-2025 | Valtoco |
| Biogen, INC. | $1,011.51 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Teva Pharmaceuticals USA, INC. | $1,003.59 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lundbeck LLC | $894.91 | 2021-2025 | Vyepti, Rexulti |
| Eisai INC. | $889.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $711.33 | 2021-2025 | Hyqvia, Gammagard |
| Alnylam Pharmaceuticals INC. | $683.46 | 2022-2025 | Amvuttra, Onpattro |
| Lilly USA, LLC | $657.57 | 2021-2025 | Kisunla, Amyvid, Reyvow |
| Genentech USA, INC. | $619.77 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $577.90 | 2021-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $523.61 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $523.01 | 2021-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $490.85 | 2021-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $490.28 | 2021-2025 | Ultomiris, Soliris |
| Banner Life Sciences, LLC | $485.76 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $446.33 | 2021-2024 | Andexxa, Wainua |
| Genzyme Corporation | $430.14 | 2021-2022 | |
| Pfizer INC. | $412.77 | 2021-2025 | |
| Horizon Therapeutics Plc | $379.15 | 2022-2023 | Uplizna |
| Janssen Pharmaceuticals, INC | $359.90 | 2021-2023 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $357.32 | 2023-2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $324.65 | 2021-2025 | Rytary, Crexont |
| Grifols USA, LLC | $320.21 | 2022-2025 | Gamunex-C |
| Kyowa Kirin, INC. | $290.48 | 2021-2024 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $278.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $271.12 | 2022 | |
| Mdd US Operations, LLC | $260.16 | 2023-2024 | Gocovri, Gocovri |
| Catalyst Pharmaceuticals, INC. | $233.42 | 2021-2024 | Fycompa, Firdapse |
| Emd Serono, INC. | $233.08 | 2021-2025 | |
| Csl Behring | $230.18 | 2021-2025 | Hizentra |
| Abbott Laboratories | $217.63 | 2022-2024 | Absolute Pro, Infinity |
| Janssen Biotech, INC. | $214.85 | 2025 | |
| Sunovion Pharmaceuticals INC. | $213.98 | 2021-2022 | |
| Tanabe Pharma America, INC. | $193.60 | 2021-2025 | Radicava |
| Sumitomo Pharma America, INC. | $193.06 | 2023-2024 | Aptiom |
| Jazz Pharmaceuticals INC. | $190.08 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $158.45 | 2021-2023 | Hetlioz, Fanapt |
| Tg Therapeutics, INC. | $146.38 | 2024-2025 | |
| Almatica Pharma LLC | $140.63 | 2021-2023 | Gralise |
| Boston Scientific Corporation | $139.46 | 2022 | |
| Cequr Corporation | $126.89 | 2023 | Cequr Simplicity |
| Aucta Pharmaceuticals, INC. | $113.41 | 2025 | Motpoly Xr |
| Currax Pharmaceuticals LLC | $104.81 | 2021-2023 | Onzetra Xsail |
| Celgene Corporation | $100.21 | 2022-2025 | Zeposia |
| Amylyx Pharmaceuticals, INC. | $90.06 | 2023 | Relyvrio |
| Merz Pharmaceuticals, LLC | $84.54 | 2024-2025 | Inbrija, Xeomin |
| Supernus Pharmaceuticals, INC. | $72.84 | 2021-2022 | |
| Axsome Therapeutics, INC. | $72.77 | 2025 | Symbravo |
| Arbor Pharmaceuticals, INC. | $65.32 | 2021 | |
| Acorda Therapeutics, INC | $57.56 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $55.55 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $49.67 | 2023 | Dysport |
| Corium, LLC | $44.16 | 2022 | |
| Novo Nordisk INC | $41.80 | 2022-2023 | Ozempic, Rybelsus |
| Adamas Pharmaceuticals, INC. | $31.70 | 2021 | |
| Impel Pharmaceuticals INC. | $24.99 | 2023 | Trudhesa |
| Microtransponder, INC. | $23.89 | 2025 | |
| Avion Pharmaceuticals | $20.07 | 2023 | Dhivy |
| Azurity Pharmaceuticals, INC. | $16.80 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chun Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.